<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03953807</url>
  </required_header>
  <id_info>
    <org_study_id>CMO-MA-EYE-0603</org_study_id>
    <secondary_id>2018-004785-33</secondary_id>
    <nct_id>NCT03953807</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effectiveness and Safety of OZURDEX® in Patients With Diabetic Macular Edema But Never Treated</brief_title>
  <official_title>A 12-month, Prospective, Open-label, Phase 4 Study to Evaluate the Efficacy and Safety of OZURDEX® (Dexamethasone Intravitreal Implant) in Treatment Naïve Patients (According to Standard Clinical Practice) With Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of OZURDEX in patients with Diabetic Macular&#xD;
      Edema when used in a real world setting in Spain and Portugal.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 5, 2019</start_date>
  <completion_date type="Anticipated">August 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in best corrected visual acuity (BCVA) 2 months (± 2 weeks) after the last injection</measure>
    <time_frame>Baseline, at Month 10 through 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in Central Retinal Thickness (CRT) 2 months (± 2 weeks) after the last injection received</measure>
    <time_frame>Baseline, at Month 10 through 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean retreatment interval in months</measure>
    <time_frame>During the 12 to 14-month study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) for CRT</measure>
    <time_frame>Baseline, During the 12 to 14-month study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC for BCVA</measure>
    <time_frame>Baseline, During the 12 to 14-month study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in the National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25)</measure>
    <time_frame>Baseline, at Month 14</time_frame>
    <description>25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question. All items are scored so that a high score represents better functioning. Original numeric values from the survey will be recoded with the worst and best possible scores set at 0 and 100 points, respectively. In this format, scores represent the achieved percentage of the total possible score, e.g. a score of 50 represents 50% of the highest possible score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with 2nd injection</measure>
    <time_frame>During the 12 to 14-month study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with 3rd injection</measure>
    <time_frame>During the 12 to 14-month study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of injections administered</measure>
    <time_frame>During the 12- to 14-month study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 3rd injection</measure>
    <time_frame>During the 12 to 14-month study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 2nd injection</measure>
    <time_frame>During the 12 to 14-month study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">83</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Ozurdex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZURDEX implant 700 μg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone Intravitreal Implant</intervention_name>
    <description>Implant 700 μg</description>
    <arm_group_label>Ozurdex</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Prior diagnosis of diabetes mellitus (type 1 or type 2)&#xD;
&#xD;
          -  Media clarity, pupillary dilation, and patient cooperation sufficient for all study&#xD;
             procedures&#xD;
&#xD;
          -  Written informed consent obtained in accordance with all local privacy requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled systemic disease&#xD;
&#xD;
          -  History of disease, metabolic dysfunction, or clinical laboratory finding giving&#xD;
             reasonable suspicion of a disease condition that contraindicates the use of the&#xD;
             investigational drug, might affect the interpretation of study results, or render the&#xD;
             patient at high risk from treatment complications&#xD;
&#xD;
          -  Patients who have been previously treated for DME (two focal laser allowed)&#xD;
&#xD;
          -  Untreated diabetes or anticipated change (increase) of antidiabetic medications during&#xD;
             the study&#xD;
&#xD;
          -  Elevated IOP or glaucoma diagnosis&#xD;
&#xD;
          -  Any active ocular infection or inflammation&#xD;
&#xD;
          -  Aphakia&#xD;
&#xD;
          -  A substantial cataract is present that is likely to be decreasing visual acuity by&#xD;
             three lines or more (i.e., cataract would be reducing visual acuity to 20/40 or worse&#xD;
             if the eye was otherwise normal)&#xD;
&#xD;
          -  Anticipated need for ocular surgery during the study&#xD;
&#xD;
          -  History of vitrectomy or incisional glaucoma surgery - Female patients who are&#xD;
             pregnant, nursing, or planning a pregnancy, or who are of childbearing potential and&#xD;
             not using a reliable means of contraception&#xD;
&#xD;
          -  Known allergy, hypersensitivity or contraindication to the study medication, its&#xD;
             components, or povidone iodine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ALLERGAN INC.</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chuc /Id# 233643</name>
      <address>
        <city>Coimbra</city>
        <zip>3004-561</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Santo Andre /ID# 233670</name>
      <address>
        <city>Leiria</city>
        <zip>2410-197</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRL Instituto de Retina e Diabetes Ocular de Lisboa. /ID# 233667</name>
      <address>
        <city>Lisbon</city>
        <zip>1150-085</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Lisboa Norte /ID# 233684</name>
      <address>
        <city>Lisbon</city>
        <zip>1649 028</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsam /Id# 233635</name>
      <address>
        <city>Viana do Castelo</city>
        <zip>4904-495</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Vila Franca de Xira /ID# 233682</name>
      <address>
        <city>Vila Franca de Xira</city>
        <zip>2600-009</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Oftalmológico Gómez-Ulla /ID# 233590</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruna</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Son Espases /ID# 233601</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Illes Balears</state>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro, Majadahonda /ID# 233597</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CLINICA UNIVERSIDAD DE NAVARRA-Pamplona /ID# 233618</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra, Comunidad</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Oftalmología Barraquer /ID# 233591</name>
      <address>
        <city>Barcelona</city>
        <zip>08021</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICOF Hospital Clinic De Barcelona /ID# 233675</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Microcirugía Ocular /ID# 233689</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Cruces /ID# 233673</name>
      <address>
        <city>Bilbao</city>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Insular de Gran Canaria /ID# 233658</name>
      <address>
        <city>Las Palmas De Gran Canaria</city>
        <zip>35016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oftalvist Moncloa /ID# 233647</name>
      <address>
        <city>Madrid</city>
        <zip>28008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vissum Madrid /ID# 233646</name>
      <address>
        <city>Madrid</city>
        <zip>28035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario San Carlos /ID# 233578</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz /ID# 233619</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio /ID# 233609</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia /ID# 233600</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Arnau Vilanova /ID# 233594</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politecnico La Fe /ID# 233613</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Araba /ID# 233693</name>
      <address>
        <city>Vitoria Gasteiz</city>
        <zip>01004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Lozano Blesa /ID# 233685</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miguel Servet University Hospital /ID# 233629</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.AllerganClinicalTrials.com</url>
    <description>Additional information on study locations near you may be found at AllerganClinicalTrials.com. For any study not on AllerganClinicalTrials.com, please contact IR-CTRegistration@Allergan.com for assistance.,To be considered as a site for current and futur</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 13, 2019</study_first_submitted>
  <study_first_submitted_qc>May 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2019</study_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>For details on when studies are available for sharing, please refer to the link below</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/abbvie/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

